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STRA13 is a pVHL-dependent bHLH transcription factor up-regulated on
the mRNA level in multiple cancer cell lines and implicated recently in
the regulation of immune cell homeostasis and autoimmunity. In search-
ing for STRA13-interacting proteins with oncogenic potential by the yeast
two-hybrid screening, we identified STAT3b as a STRA13-binding partner.
We showed that STRA13 binds predominantly to phosphorylated (active)
STAT3 a and b isoforms via its HLH and C-terminal regions. We also
found that STRA13 was able to activate transcription from STAT-depen-
dent cis-elements. Expression of endogenous STRA13 was shown to be
cytokine-inducible, consistent with STRA13 involvement in STAT-depen-
dent transcription regulation. We demonstrated that the STAT3-regulated
promoter of the pro-apoptotic Fas gene was activated upon STRA13
over-expression and that co-expression of STRA13 with STAT3b or
STAT3a modulated the transcriptional outcome. Forced expression of
STRA13 induced apoptosis, in agreement with the STRA13 activation
effect on the Fas promoter. Simultaneous expression of STRA13 and
STAT3b resulted in alleviation of the STRA13 pro-apoptotic effect. Thus,
for the first time, we identify STRA13 as a STAT3 partner and provide a
consistent line of evidence for STRA13 involvement into regulation of
apoptosis via the STAT pathways.
q 2004 Elsevier Ltd. All rights reserved.
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Introduction
Inactivation of von Hippel–Lindau tumor sup-
pressor protein (pVHL) is critical for the develop-
ment of certain kidney, CNS, and adrenal tumors.1
Recent elucidation of pVHL’s pivotal role in
regulating expression of numerous genes, via
HIF1a proteolysis,2 has helped in delineating
some of the pVHL biological activities essential
for carcinogenesis. It is now clear that while certain
pVHL targets, such as VEGF and PDGF, drive
tumor-promoted angiogenesis,3,4 others, such as
GLUT-1,4 glycolitic enzymes,5 and carbonic anhy-
drases CA 9 and CA 126,7 are responsible for
the adjustment of tumor metabolism to hypoxia
and acidification (the Warburg effect). We have
recently identified a novel pVHL target with an as
yet unclear role in tumor progression: the basic
helix-loop-helix transcription factor STRA13.6,8 The
mouse ortholog of human STRA13 was originally
characterized as a transcriptional repressor.9
Transcriptional repression activity of Stra13 in
NIH 3T3 cells was shown to be associated with
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growth arrest and down-regulation of c-Myc.10
Molecular mechanisms of Stra13 action involve
interaction with members of the general transcrip-
tional machinery, TBP and TFIIB,9 and with the
transcription factor USF.11 Multiple stimuli and
mechanisms that regulate the amount of Stra13 in
the cell are indicative of its paramount importance
for cell function. On the mRNA level, Stra13 is
regulated by retinoic acid, cAMP, serum starvation,
trichostatin A (a specific histone deacetylase inhi-
bitor) and hypoxia.8–10,12,13 On the protein level, it
is tightly controlled by the hUBC9-proteasome
degradation machinery.8 There is mounting
evidence that cell differentiation is a STRA13
major biological function. Thus, STRA13
expression has been found to be up-regulated in
differentiating human embryonic chondrocytes11
and in retinoic acid-induced neuronal differen-
tiation of P19 mouse embryonal carcinoma cells.9
It was shown recently that hypoxia-induced
STRA13 serves as an effector of HIF-1 during
inhibition of adipogenesis by hypoxia.14 Targeted
disruption of Stra13 unexpectedly produced a
systemic lupus-like immune disorder highlighting
the crucial role of this protein in immune system
regulation.15 The ineffective elimination of acti-
vated T and B-lymphocytes, as the main result of
Stra13 inactivation, led to lymphoid organ hyper-
plasia, lymphocytic infiltration, and tissue destruc-
tion. Another group of researchers characterized
Stra13 as a negative regulator of B-lymphocyte
activation.16
Here, we report on the functional interaction
between STRA13 and STAT3. The STAT proteins
(signal transducers and activators of transcription)
were identified in the last decade as transcription
factors that play a pivotal role in the regulation of
the immune system, hematopoiesis, neurogenesis
and embryogenesis by mediation of virtually all
cytokine signaling. JAK-STAT signal transduction
events usually require activation of cytoplasmic
STAT proteins in response to cytokines through
tyrosine phosphorylation, formation of homo- and
heterodimers, and entering the nucleus. However,
recent experiments revealed the existence of
nucleocytoplasmic shuttling of unphosphorylated
STATs in the absence of cytokines.17 In the nucleus,
STAT complexes work coordinately with other
transcriptional co-activators and transcription
factors to enhance transcriptional initiation. STAT3
was initially identified as acute phase response
factor (APRF), an interleukin-6 (IL-6)-inducible
protein that binds upon activation to class 2 IL-6
responsive elements.18 For the last few years,
reports have been accumulating that show
STAT30s key role in a variety of different, some-
times opposite, biological processes from cell
survival and cell-cycle transition to growth arrest
and apoptosis.19 The abnormal activation of STAT3
is becoming more frequently associated with
unrestricted cell growth and malignant
transformation.20,21 STAT3 has been classified as an
oncogene because constitutively active Stat3 can
mediate oncogenic transformation in cell culture
and in nude mice.21 Two STAT3 protein isoforms,
STAT3a (p92) and STAT3b (p83), have been
identified in human and mouse.22–24 The mRNA
encoding STAT3b has a 50 nucleotide deletion at
the 30 end due to alternative splicing. The resulting
protein lacks the C-terminal 55 amino acid residues
of STAT3a, which are replaced by seven unique
amino acid residues.25 The deleted region com-
prises the transcriptional activation domain.
Studies comparing the properties of these two
phosphorylated isoforms uncovered a markedly
elevated STAT3b DNA-binding activity in com-
parison with STAT3a.26 Biological activity of
STAT3b appears to vary in different cells. While in
some cases STAT3b was shown to lack
transcriptional activity, in other studies it was able
to activate promoters of certain genes in a cell
type-specific manner.22,23,27 The role of the STAT3b
isoform in oncogenesis also seems to be cell type-
specific. Over-expression of STAT3b efficiently
blocked activation of STAT3 signaling and led
to growth suppression in melanoma, prostate,
ovarian and breast cancers in vitro and in vivo.28–30
However, expression of the STAT3b isoform in
acute myeloid leukemia patients was found to be
associated with shorter overall patient survival.31,32
It can be concluded, therefore, that the resulting
biological effect of STAT3 transcriptional activity
depends largely on the STAT3a/STAT3b ratio in
the cell and on a variety of other transcription
factors, co-activators and repressors that may
modify the activity of STAT3 proteins.
Our recent findings, linking STRA13 expression
with carcinogenesis, encouraged us to pursue its
putative role in tumor progression. Because
STRA13 protein-partners were poorly investigated,
we initiated a study of the potential STRA13
networks using the yeast two-hybrid system. We
report here that STRA13 binds phosphorylated
STAT3b and STAT3a isoforms. We further demon-
strate that STRA13 activates transcription from
STAT-dependent cis-elements and show that
co-expression of STAT3b and STRA13 results in
suppression of STRA13-dependent transactivation.
We also show that expression of the STRA13 gene
is cytokine-regulated implicating STRA13 in the
JAK-STAT signal transduction pathway. Finally,
our data imply STRA13 involvement in the control
of apoptosis via STAT3-dependent regulation of
the Fas promoter. We suggest, therefore, that
inappropriate co-activation of STRA13 and STAT3
may lead to oncogenic transformation.
Results
STRA13 interacts with STAT3b, the short
isoform of STAT3
We searched for STRA13-binding proteins using
the yeast two-hybrid system and a human fetal
kidney cDNA library.8 Out of 186 positive clones,
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which we identified, one represented a full-length
(,3.2 kb) STAT3b cDNA. The specific interaction
between STRA13 and STAT3b in yeast was
confirmed by co-transformation of both the
BD-STRA13 and AD-STAT3 constructs into yeast
cells resulting in reconstitution of GAL4 transcrip-
tion activity (data not shown). To verify the
interaction between pSTRA13 and pSTAT3b in
mammalian cells, we fused their N termini with
FLAG-tag and HA-tag, respectively, in pCMV2
and pCMV-HA expression vectors. Co-immuno-
precipitation confirmed that the STAT3b-HA
protein specifically interacted with the STRA13-
FLAG protein (Figure 1(A), line 2). No precipi-
tation was observed when the empty pCMV2
vector was co-transfected with STAT3b-HA vector
(Figure 1A, line 1).
STAT3b associates with the HLH and the
C-terminal regions of STRA13
To define the STRA13 domain(s) responsible
for binding to STAT3b we used a set of STRA13
FLAG-fused deletion constructs (Figure 1A,
upper part). The STAT3-HA and each of the
STRA13 deletion variants were transiently co-
transfected into 293T cells. Twenty-four hours after
transfection, the cells were treated with the protea-
some inhibitor ALLnL and subjected to co-immu-
noprecipitation analysis. ALLnL treatment was
performed to stabilize the truncated proteins,
since we have shown that truncation of either
STRA13 terminus leads to a sharp decrease in the
protein half-life.8 The apparently stronger inter-
action of the 68–412 construct, lacking the
N-terminal basic region, with STAT3b protein is
surprising, but it may reflect a conformation
dependency for interaction (Figure 1A). Mutants
with extended N-terminal deletions, which
included the HLH domain (construct 123–412)
and two a-helices (constructs 184–412 and 259–
412) failed to bind to STAT3b (Figure 1A, lines
4–6). Interestingly, the mutant with the most
extended deletion, that comprised the bHLH
domain and all three a-helices (construct 293–
412), partially restored interaction with STA3b
(Figure 1A, line 7), thus implicating the C-terminal
domain in the STRA13–STAT3 interaction. The
1–299 construct, lacking the C-terminal domain,
did not show any binding activity (Figure 1A,
line 8). In summary, these experiments clearly
demonstrate that the helix-loop-helix region
(65–108 residues) and the C-terminal part
(300–412 residues) of STRA13 are essential for
STAT3-binding.
STRA13 binds to the tyrosine-phosphorylated
forms of STAT3b and STAT3a proteins
The phoshorylation status of the STAT3 molecule
in the cell reflects its transcriptional activity. To
find which of the STAT3 isoforms preferentially
binds to STRA13 protein, we treated cells with
sodium pervanadate (PV), a commonly used pro-
tein–tyrosine phosphatase inhibitor.33 A 15 minute
pervanadate treatment of 293T cells transfected
with STRA13-FLAG and STAT3-HA constructs
dramatically increased the pool of tyrosine-
phosphorylated proteins. Co-immunoprecipitation
revealed that inhibition of the tyrosine phospha-
tases boosted the amount of STAT3b protein that
binds to the STRA13 protein, as compared to that
in the untreated cells (Figure 1B). Re-probing of
the same membrane with the antibodies specific
to phospho-tyrosine showed that most of the
co-immunoprecipitated STAT3b protein had
phosphorylated tyrosine (Figure 1B).
The activation of STAT3 requires tyrosine phos-
phorylation at residue 705. To confirm that
STRA13 binds mostly to phosphorylated STAT3,
we used STAT3a mutated on tyrosine 705.
Co-expression of STRA13-FLAG and Y705-STAT3
in 293T cells with subsequent co-immuno-
precipitation revealed that mutation of tyrosine
705 practically abrogates binding of STAT3 to
STRA13 (Figure 1C).
Overall, this study clearly demonstrates that
STRA13 interacts with both the STAT3a and b
isoforms and shows a strong binding preference
for transcriptionaly active (phosphorylated)
proteins.
STRA13 activates transcription from STAT-
responsive elements GAS, ISRE and STAT3
Preferential binding of STRA13 to activated
forms of STAT3 implicates the STAT3/STRA13
complex in transcription regulation. In the search
for transcription sites common to STAT3 and
STRA13, we studied the ability of the STRA13 to
regulate STAT-dependent cis-elements. For this,
we employed the Mercury JAK-STAT Pathway
Profiling system (Clontech), which includes the
enhancer elements GAS (interferon-g activating
sequence), ISRE (IFN-stimulated responsive
element) and STAT3 (a modified GAS sequence),
each introduced as three tandem copies upstream
of the TA promoter in a luciferase reporter vector
(Figure 2A). We showed that co-transfection of
293T cells with the STRA13-FLAG expression
construct and a reporter construct containing the
GAS, ISRE, or STAT3 elements resulted in a
25-fold, 40-fold, and fivefold activation of the
basal reporter gene expression, respectively (Figure
2B), in a STRA13 dosage-dependent manner.
Saturation was achieved at ,0.8 mg per well in
six-well plates (Figure 2C). No cytokine stimulation
was required to boost the STRA13-dependent
transcription activation from STAT-responsive
elements. As a positive control, we used luciferase
reporter vectors with a c-myc or an E2F-responsive
cis-element inserted upstream of the TA promoter
(Clontech, Mercury Cell Cycle Profiling System).
As a result, strong suppression of luciferase
activity (from tenfold to 50-fold) by STRA13 over-
expression was reported in the same 293T cells
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Figure 1. STRA13 interacts with the STAT3b protein in vivo. A, Identification of the STAT3b binding sites within the
STRA13 molecule. Indicated portions of STRA13 were fused to FLAG-tag in the pCMV2 vector and co-transfected with
the STAT3b-HA construct into 293T cells. Immunoprecipitation with anti-FLAG antibodies and analysis of immune
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(data not shown). Luciferase vector with no
insertion upstream of the TA promoter served as
a negative control and showed no change in
luciferase activity upon STRA13 overexpression
(Figure 2B). These data provide direct evidence
that STRA13 may serve as a powerful trans-
activator of specifically STAT-dependent cis-
elements.
complexes by Western blotting using HA-antibodies were performed as described in Materials and Methods.
Truncated proteins that retained the ability to interact with STAT3b are boxed. Filled rectangles on the schematic
diagram of the STRA13 protein represent the regions important for binding to STAT3b. B, STRA13 protein preferen-
tially binds the phosphorylated isoform of the STAT3b protein. 293T cells were co-transfected with the STRA13-
FLAG and the STAT3b-HA overexpression plasmids. Twenty-four hours post-transfection cells were split into two
plates and on the next day one plate was treated with sodium pervanadate for 15 minutes while the other was used
as a control. The immunoprecipitation (IP) procedure was performed as described above. Anti-FLAG antibodies
were used for IP, antibodies indicated on the sides of each panel were used for Western analysis. C, Y705 mutation
abrogates binding of STRA13 to STAT3a. 293T cells were transfected with the STRA13-FLAG plasmid and with
STAT3a or Y705/STAT3a plasmids. IP and followed Western blot were performed as described above. IP with mouse
IgG was used as a control. W, Western blot; a-FLAG, anti-FLAG Abs; a-HA, anti-HA Abs, a-phospho-STAT3, anti-
phospho-STAT3 Abs; a-STAT3a (H-190), anti-STAT3 antibodies, a-Phospho-Y, anti-phosphotyrosine antibodies.
       
Figure 2. STRA13 stimulates transcription from STAT-dependent cis-elements. A, Schematic illustration of the
luciferase reporter gene driven by STAT-dependent cis-elements used in the study. Each element is known to preferen-
tially bind indicated STAT homo- or heterodimeric complexes. B, Overexpression of STRA13 stimulates transcription
from all studied STAT-dependent cis-elements. 293T cells were transiently co-transfected with the indicated luciferase
plasmids and STRA13-FLAG or empty plasmids. The experiments were repeated at least five times, error bars indicate
the standard deviation of mean values. C, STRA13 activates transcription from cis-elements in a STRA13 dosage-
dependent manner. The ISRE-luc reporter and increased concentrations of STRA13-FLAG plasmid were co-transfected
into 293T cells. The pCMV2-FLAG vector was used as a control. D, Analysis of the transcription activation domain in
STRA13. Various deletion mutants of STRA13 were assessed for their ability to activate the ISRE cis-element by lucifer-
ase assay as described above with the ISRE-luc and STRA13 mutants introduced into 293T cells. The experiments were
repeated three times; error bars indicate the standard deviations. STRA13 mutants are designated according to the
amino acid residues positions of their N and C termini. Fold induction was calculated in comparison with the basal
luciferase activity obtained with the pCMV2 vector.
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The basic domain and the C-terminal region of
STRA13 are responsible for transcription
activation from cytokine-responsive elements
Since the ISRE element in our system was the
most sensitive to STRA13 overexpression, we used
the ISRE-luciferase assay for mapping of the
STRA13 regions responsible for transcriptional
activation. 293T cells were transiently co-trans-
fected with ISRE-luc plasmid and with different
STRA13 deletion constructs (Figure 2D). In this
experiment, ALLnL treatment for 24 hours prior
to the lysates preparation was also used to prevent
degradation of the STRA13 mutant (see above).
We found that truncation of the N-terminal DNA-
binding basic region (construct 68–412), as well as
the extension of the N-terminal deletion (constructs
123–412, 184–412, 259–412, 293–412), abrogated
the ability of STRA13 to activate the reporter gene
(Figure 3D). Truncation of the C-terminal 112
amino acid residues (construct 1–299) drastically
decreased the STRA13 transcriptional activity in
the ISRE-luc assay (sevenfold luciferase induction),
compared to the effect of the full-length STRA13
(30-fold luciferase induction). These data illumi-
nate the critical importance of the N-terminal
basic domain for STRA13 transactivation function.
Transactivation ability of the C-terminal domain,
which shows no similarity to any known protein
motif, requires further investigation.
STRA13 expression is induced by cytokines
STRA13’s ability to activate cytokine-responsive
elements has raised the question of cytokine’s
possible involvement in the regulation of STRA13
transcription. It was demonstrated that promoters
of certain transcription factors (c-myc, nmi, pim1,
etc.) are activated with cytokines through the JAK-
STAT pathway34–36 while the protein product of
the cytokine-activated pim1 gene was shown to
bind STAT proteins.37 Context analysis of the
STRA13 promoter revealed putative binding sites
for cytokine-inducible STATs and c-Myc (data not
shown). Altogether these facts prompted us to
assess cytokine involvement in the regulation of
STRA13 transcription. In our search for a model
cell line that could be used in this study, we found
that the natural killer IL-2-dependent cell line
NK92 is responsive to multiple cytokines as deter-
mined by expression of IFN-g (data not shown).
In our experimental assay NK92 cells were treated
with recombinant IL-1b, IL-2, IL-4, IL-6, IL-7,
IL-12, IL-15 IL-18, IL-21, and TNF-alpha and
IFN-beta. After three hours of incubation, the
level of STRA13 mRNA was assessed by Northern
analysis following densitometry analysis. As
shown in Figure 3, IL-2, IL-6, IL-12, IL-15,
TNF-alpha, and IFN-beta significantly enhanced
STRA13 mRNA expression while IL-1beta, IL-4,
IL-7, IL-18, and IL-21 effects were less pronounced,
if visible at all, after three hours of stimulation with
the indicated cytokines. Thus, this experiment
clearly demonstrates contribution of at least IL-2,
IL-6, IL-12, IL-15, TNF-alpha, and IFN-beta to the
regulation of STRA13 mRNA expression corrobor-
ating our data on STRA13 involvement in STAT-
dependent pathways.
Roles of STRA13 and STAT3 in the regulation
of Fas transcription
The cell surface receptor Fas and its cognate
ligand FasL play essential roles in apoptosis regu-
lation and are required for immune system homeo-
stasis. In cooperation with c-Jun, STAT3 down-
regulates the transcription of the Fas receptor
promoter in melanoma cells contributing to the
resistance of these cells to apoptosis.38 Targeted dis-
ruption of Stra13 showed that this gene product is
also directly or indirectly involved in Fas-FasL
mediated apoptosis,15 apparently by regulating
the FasL level. The role of STRA13 in Fas receptor
regulation, however, remained unclear. To
determine possible involvement of STRA13 in the
regulation of Fas receptor as a known STAT3 tran-
scriptional target, we employed Fas-Luc reporter
constructs and the human Jurkat cell line. Our
choice of Jurkat cells, which have an activated
T-cell phenotype, as a model cell line is based on
the fact that Stra13 was shown to play a crucial
role in the Fas-mediated apoptosis of activated T
and B cells.15 Forced expression of STRA13 led to
a three- to fivefold increase in Fas promoter-driven
reporter activity in a STRA13-dosage-dependent
manner (Figure 4). STAT3b overexpression
also resulted in promoter activation, while
co-expression of STRA13 and STAT3b led to
Figure 3. The endogenous
STRA13 mRNA level is increased
after treatment with various cyto-
kines. Responsiveness of STRA13
expression to cytokines was studied
in IL-2-dependent NK92 cells. After
three hours of incubation with
the indicated cytokines the total
RNA was extracted and the level
of STRA13 mRNA was assessed
by Northern analysis. The actin
mRNA was used as a loading
control.
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,1.5-fold suppression of the Fas-luc basal tran-
scription (Figure 4). Under the same conditions,
the expression of STAT3a repressed Fas-depen-
dent-Luc activities but failed to repress STRA13-
dependent activation of the Fas promoter to the
same extent as STAT3b (Figure 4). These results
imply that the STRA13/STAT3b and STRA13/
STAT3a protein complexes have different bio-
logical properties. In line with the data on mela-
noma cells,38 IL-6 treatment did increase, but not
significantly, the activation of the Fas promoter by
the studied proteins (data not shown).
Truncation of the N-terminal basic domain
(construct 68–412) or COOH-terminal domain of
STRA13 (construct 1–299) led to complete abroga-
tion of the STRA13 activating function (data not
shown). These data are in agreement with our pre-
vious findings of the critical roles of these domains
in the STRA13 transactivation function (Figure 2D).
STRA13 over-expression causes apoptosis
Since Fas expression directly regulates Fas/FasL-
mediated apoptosis, our next step was to investi-
gate whether cells over-expressing STRA13
undergo apoptosis. To assess the involvement
of human STRA13 in regulation of apoptosis via
transient expression, we used 293T cells, distin-
guished with a high tranfection rate.
We applied the TUNEL assay to estimate the
proportion of 293T cells that undergo apoptosis
during transient expression of the mock pCMV2-
FLAG vector, the STRA13-FLAG, and the 259–
412-FLAG constructs. Apoptotic cells were counted
three days after transient transfection. Cells trans-
fected with STRA13-FLAG showed a fourfold
increase in apoptotic cells (Figure 5A) as compared
to the mock vector, whereas transfection with the
C-terminal part of STRA13 protein did not change
the amount of apoptotic cells, compared to the con-
trol. The extent of the STRA13 effect on apoptosis
in this assay is, most likely, underestimated
because of the limited efficiency of transient trans-
fection (,60%). Immunostaining demonstrated
that many of the cells expressing STRA13/FLAG
are TUNEL-positive and have apoptotic dense
nuclei. An apoptotic phenotype was associated
with altered localization of STRA13, which
resulted in its dispersed dotted distribution in
cytoplasm (Figure 5B). To confirm the involvement
of STRA13 in Fas-dependent apoptosis by regu-
lation of the endogenous Fas gene expression,
quantitative RT-PCR analysis was applied to the
same set of transfected cells. We showed that
STRA13 overexpression resulted in the increase of
the endogenous Fas expression in 293 cells when
compared to experiments with empty vector or
with the STRA13 construct lacking the bHLH
domain (Figure 5C). To investigate the effect of
STRA13 and STAT3b co-expression on
the apoptotic process, we compared the amount of
apoptotic cells in 293T cell line transfected with
STRA13 and STAT3b constructs separately or
simultaneously. Transient expression of either
STRA13 or STAT3b during the following 48 hours
resulted in an increase in apoptotic cells compared
to the mock transfection, while co-expression of
these two proteins resulted in the decrease of
apoptotic cells, compared to the effects of STRA13
or STAT3b alone (Figure 5D). Co-expression of
STAT3b with the N-truncated STRA13 version did
not lead to any significant change in the amount
of apoptotic cells, compared to STAT3b alone.
These data are in line with our observation that
STRA13 and STAT3b co-expression decreases
luciferase transcription from the Fas-luc promoter,
while each of these proteins alone has a trans-
activating effect. These data, overall, provide
strong support towards our hypothesis that
STRA13, along with STAT3, functions as a
regulator of the Fas-dependent apoptotic pathway.
Discussion
Our study provides biochemical and functional
evidence of association between the bHLH tran-
scription factor STRA13 and the transcriptional
regulator STAT3. We demonstrate that binding of
STRA13 to STAT3b takes place in the mammalian
cell and recruits the helix-loop-helix and the
C-terminal domains of STRA13. While the HLH
domain is evolutionarily conserved and is known
to serve in the protein–protein interaction func-
tion, involvement of the C-terminal domain is
Figure 4. Co-expression of STRA13 with STAT3a or
STAT3b produces different effects on STRA13-dependent
activation of the 21.7 kb Fas-promoter. Jurkat cells were
transfected with the 21.7 kb Fas-luc reporter construct
and the indicated amounts of the STRA13, STAT3a or
STAT3b plasmids. The results shown are representative
of five independent experiments.
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especially interesting because no evolutionary con-
served regions have been recognized in this area. It
is possible that the C-terminal domain is respon-
sible for the specificity of STRA13 interaction with
STAT3. Two STRA13 homologs have been
described recently, (SHARP-139,40 and DEC241),
with their HLH domains almost identical (97–
100%) with that of STRA13 and their C-terminal
regions highly diverged. It would be interesting to
find out if these proteins can interact with the
STATs, and, if so, to evaluate the possible role of
the C terminus in the specificity of such inter-
actions. It has been shown that transcriptional co-
activators, such as CBP, p300, MCM5, and NcoA/
SRC1a42–45 bind to STATs via their C-terminal trans-
activation domain (TAD). Here, we report that
STRA13 binds to the STAT3 isoform b that lacks
the C-terminal TAD. The fact that STAT3b and
STRA13 were able to interact without the TAD
region suggested a repressing rather than activat-
ing potential for the STRA13/STAT3 complexes,
similar to the described STAT5/SMRT complex
that is formed through the STAT5 N-terminal
coiled-coil region.46
Taking into consideration our finding that the
transcriptional regulator STRA13 exhibited a
higher affinity to the transcriptionally active, or
phosphorylated, isoforms of STAT3, we searched
for the common transcriptional targets that can be
regulated with the STRA13/STAT3(PY) complex.
First, we investigated STRA13 activity on the
known STAT-dependent cis-elements. These
elements can be classified into two groups. The
prototype of the first one is the interferon-stimu-
lated response element ISRE,47 which STAT1/
STAT2 heterodimers were shown to bind. STAT1,
STAT2, STAT3, STAT4, STAT5a, STAT5b, and
STAT6 protein complexes were shown to bind
another class of cis-elements, known as GAS
motifs.48 The STAT3 element, a variant of the GAS
motif that preferentially interacts with STAT3, was
also used in the current study.
Figure 5. STRA13 overexpression
induces cell death in 293T cells.
A, STRA13-FLAG, 259-412-FLAG
(N-truncated STRA13) plasmids or
empty pCMV2 vector were trans-
fected in 293T cells. At 48 hours
post-incubation, cells were cultured
on coverslips. Cell death was
assayed by the TUNEL method.
The means of three independent
experiments are shown. B,
Immunostaining of TUNEL-
assayed 293T cells from the experi-
ment described in A with an anti-
FLAG M2 Abs (red) showing
STRA13/FLAG positive cells. DAPI
was used to counterstain the nuclei.
The arrows indicate apoptotic (A)
and normal (N) STRA13-positive
cells. C, Quantitative RT-PCR per-
formed on RNA isolated from the
cell lines transiently transfected
with STRA13 construct or empty
vector or STRA13 mutant construct
as controls. 18 S rRNA expression
was used as an internal standard.
D, The effect of STRA13 and
STAT3b co-expression on the
apoptotic process in 293T cells tran-
siently transfected with the indi-
cated plasmids. Cell death was
assayed by the TUNEL method at
48 hours post-incubation. The
means of three independent experi-
ments are shown.
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STRA13-dependent transactivation, shown on
the ISRE, GAS, and STAT cis-elements in 293T
cells, demonstrated STRA13 ability to induce tran-
scription. This transactivation was shown only for
the STAT-dependent cis-elements, while STRA13
suppressed, as expected, transcription from other
cis-elements used in the study (c-myc-dependent,
E2F-dependent elements). The ability of STRA13
to activate STAT-dependent promoters without
cytokine stimulation may be explained by a self-
sufficiency of this nuclear protein for transactiva-
tion once it is transcriptionally up-regulated. The
basic STRA13 domain, generally considered to
possess a DNA-binding function,49 was found in
our study to be primarily responsible for the trans-
activation from STAT-responsive elements. Thus, it
may be considered as the additional evidence that
STRA13 is able to activate the promoter directly
through DNA binding. The C-terminal part of the
protein, although dispensable, was also shown to
play a role in the transactivation process. Until
recently, Stra13 was considered to be a transcrip-
tional repressor.9–11 Targeted disruption of Stra13,
however, presented indirect evidence of its
involvement in transcription activation of certain
genes. For example, Stra132/2 , in comparison with
wild-type CDþ T cells, produced less IFN-g and
IL-4. Reintroduction of Stra13 in these cells fully
rescued IFN-g and IL-4 expression in STRA132/2
cells upon their differentiation into Th1 cells, indi-
cating that expression activation of these cytokines
depends on the Stra13 function.15 In line with
these observations, our experiments on STAT-
dependent cis-elements produced the first direct
evidence of STRA13 potent transactivation
properties.
Binding of STRA13 to cytokine-regulated cis-
elements prompted us to examine the effect of
cytokines on the STRA13 mRNA expression. It
was reported that transcription factors c-myc, nmi
and pim-1 are transcriptionally activated upon
cytokine stimulation through the JAK-STAT
pathway,35,50 while the product of one of these
genes, pim-1 was shown to bind STAT proteins.37
Therefore, the fact that the STRA13 promoter con-
tains putative binding sites for cytokine-inducible
STATs, c-Myc and NF-kappaB, was another
indirect point of evidence of cytokine involvement
in STRA13 transcriptional regulation. We demon-
strated that endogenous STRA13 expression was
significantly increased upon treatment with IL-2,
IL-6, IL-12, IL-15, TFN-alpha, and IFN-beta. Such
a broad spectrum of cytokines affecting STRA13
transcription implies an important role(s) for
STRA13 in functionally pleiotropic processes of
cell growth, differentiation, apoptosis, immune
response, etc. regulated by STATs. It is known, for
instance, that IL-2 and IL-15 activate STAT5, IL-6
is involved in STAT3 activation, IL-12 is respon-
sible for STAT4 phosphorylation, and IFN-beta
activates the STAT1 transcription factor.51,52 It was
also found recently that TNF-alpha, along with its
known role in NF-kappaB activation, induces the
activation of the tyrosine kinases Jak1 and Tyk2 in
human B cells subsequently activating STAT3 and
STAT5b proteins.53 Taken together with the data
on STRA13-dependent activation of a variety of
STAT-specific cis-elements, these observations
emphasize STRA13 importance as an integral part
of the STAT-signaling pathways.
Our next step was to pursue the functional sig-
nificance of STRA13 interaction with STAT3 by
studying their activity on the STAT3-specific Fas
promoter. In several studies oncogenic function
of STAT3 signaling was associated with anti-
apoptosis.54–56 V.I. et al. have recently shown that
STAT3 anti-apoptotic activity could be mediated
through suppression of Fas expression in mela-
noma cell lines.38 The pro-apoptotic role of the
Stra13 gene was recently proposed based on an
experiment on targeted gene disruption. Mouse
Stra132/2 CD4þ T cells failed to appropriately up-
regulate FasL expression, leading to resistance of
activated T and B cells to the Fas-mediated apopto-
sis and, subsequently, to their accumulation.15 The
resulting phenotype, a lupus-like systemic auto-
immunity, was similar to that produced by
mutations in the Fas or FasL genes,57,58 illuminating
Stra13’s pivotal role in the regulation of peripheral
T cells apoptosis. The association of STRA13 with
activated STAT3 (this study) and the implication
of both proteins in the Fas-dependent apoptotic
molecular pathway15,38 prompted us to elucidate
the possible role of STRA13/STAT3 in this process.
In our experiments with the Fas promoter per-
formed on Jurkat cells, STRA13 over-expression
resulted in transcriptional activation of the promo-
ter. STAT3b also demonstrated a significant, albeit
less pronounced, activation effect. In agreement
with our data, the STAT3b isoform as a dominant-
negative of STAT3a was also reported to activate
transcription from the Fas promoter in melanoma
cell lines.38 STAT3a, in our experiment, suppressed
the Fas-luc promoter, which was also in line with
the experiments on melanoma cells.38 STAT3a
and b possess different biochemical properties
and have non-overlapping biological functions.
STAT3b, a constitutively activated isoform of
STAT3a that lacks the C-terminal domain, attenu-
ates STAT3a transcriptional activities.23,59
Unexpectedly, co-expression of both STRA13
and STAT3b led to suppression of the transcrip-
tion. Co-expression of STRA13 and STAT3a, on
the other hand, alleviated the STAT3a-dependent
suppression (Figure 4). These data suggest that
the balance between STRA13 on one side and
STAT3a/STAT3b on the other plays an important
role in the regulation of the Fas promoter and,
thus, may contribute to the cell survival decision.
Impact of STRA13 expression on apoptosis was
than tested in a cell culture functional assay. Using
the TUNEL assay, we showed that STRA13 tran-
sient expression caused a , fourfold increase in
apoptotic cells, clearly implicating STRA13 in
apoptosis induction. We also obtained direct con-
firmation of the regulation of Fas expression by
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STRA13 from the quantitative RT-PCR analysis of
endogenous Fas expression. STRA13 overexpres-
sion increased the amount of Fas mRNA compared
to overexpression of the empty vector.
The paradoxical effect of STRA13 and STAT3b
co-expression on the Fas-luc promoter found its
support in our functional apoptosis assay leading
to decreases in apoptotic cells number when com-
pared to the effects of the proteins expressed alone
(Figure 5D). Further experiments are required for
deciphering the molecular mechanisms of this
effect.
In conclusion, we characterize STRA13 and
STAT3 as protein partners involved in complex
regulation of STAT transcriptional targets. Our
study provides a consistent line of evidence that
the bHLH transcription factor STRA13 may serve
as a transcriptional activator as an integral part of
the STAT transcriptional network. Through this
network STRA13 may contribute to the regulation
of critical processes of cell survival and growth,
known to be disregulated in cancer cells. Under
the most simplistic scenario that may be proposed,
STRA13 mRNA overexpression caused by pVHL
deficiency, hypoxia or other stimuli may have
either an apoptotic or anti-apoptotic effect,
depending on the availability of activated STAT
isoforms. Indeed, many cancer cells are known to
express high levels of STAT3b, which may interact
with STRA13 and suppress apoptosis via Fas-
dependent mechanism. STATs, however, are also
implicated in regulation of growth arrest through
p19 and p21 and G1 to S cell cycle progression
through Pim or c-Myc.18 Thus, more investigation
into the STAT network is required to elucidate all
possible consequences of STRA13/STAT3
interaction.
Materials and Methods
Cell lines and reagents
The human 293T embryonic kidney cell line, the
mouse fibroblasts NIH3T3 cell line and the T-lymphoma
Jurkat-E6 cell line were obtained from the American
Type Culture Collection (Rockville, MD) and cultured
in media recommended by the supplier. The human
NK-92 natural killer cell line was maintained in RPMI
1640 medium containing 10% (v/v) fetal calf serum,
2 mM L-glutamine, 100 i.u. of penicillin, 100 mg of strep-
tomycin, and 200 i.u. of recombinant human IL-2. Before
cytokine stimulation experiments, cells were maintained
at a density of 106 ml21 in medium lacking IL-2 for
14 hours. IL-2 (100 i.u./ml), IL-12 (100 i.u./ml), and
IL-18 (100 ng/ml) were used for stimulation. The mono-
clonal anti-FLAG M2 antibody was purchased from
Sigma. The rat monoclonal HA (clone 3F10) antibody
was purchased from Roche Molecular Biochemicals,
rabbit polyclonal phosphotyrosine antibodies were pur-
chased from Cell Signaling Technology, rabbit polyclonal
STAT3 (H-190) antibodies were purchased from Santa
Cruz Biotechnology, Inc. Secondary anti-mouse and
anti-rabbit IgG for Western blots were purchased from
Santa Cruz Biotechnology, secondary Alexa Fluor 488
anti-mouse IgG for immunostaining of cells were pur-
chased from Molecular Probes, Inc.
Plasmid constructs
STRA13 and a series of its deletion mutants were gen-
erated by amplification of the fragments from the human
cDNA and cloned into the EcoRI-XbaI sites of pCMV2-
FLAG vector. The constructs have been verified by
sequencing. STAT3b-pCMV-HA plasmid for STRA13
interactors was generated by subcloning of the 3.2 kb
EcoRI-XhoI insertion from the pACT2 plasmid obtained
by screening of the fetal kidney cDNA Matchmaker
cDNA library (Clontech) for STRA13 interactors. The
luciferase reporter plasmids with the cytokine-respond-
ing cis-acting enchancer elements inserted before TATA-
box were purchased from Clontech. The luciferase
reporter driven by 1.7 kb or 460 bp of the human Fas
promoter were kindly provided by Dr L. B. Owen-
Schaub (Division of Biomedical Sciences, University of
California, Riverside, CA). Stat3a inserted into pRcCMV
plasmid was obtained from Dr J. Bromberg (Rockefeller
University and Memorial Sloan Kettering Cancer Center,
New York, NJ).
Immunostaining and TUNEL assay
293T cells were transiently transfected with STRA13/
pCMV2, 259-412/pCMV2 (N-truncated STRA13
construct) or an empty pCMV2 vector using Lipo-
fectamine2000 (Gibco BRL). Seventy-two hours post-
transfection cells were cultured on coverslips overnight.
In the morning cells were washed in PBS, fixed in 4–7%
(w/v) paraformaldehyde for 30 minutes and perme-
abilized with 0.1% (v/v) Triton X-100 for five minutes.
After pre-incubation with 1% (v/v) fetal bovine serum,
cells were immunostained with anti-FLAG M2 mouse
mAb. Goat anti-mouse antibodies with Alexa Fluor TM
594 (red) were used to visualize the anti-FLAG mouse
mAb. For TUNEL assay, washed cells were treated
according to the protocol for In Situ Cell Death Detection
Kit (Roche). Fluorescein-12-dUTP-labeled DNA (green)
was visualized by confocal microscopy (60 £ ). Cells
were mounted in mounting media with DAPI for nuclei
staining (Vector). At least 2000 cells from ten different
fields were examined in each experiment, and the cell
death was expressed as a percentage of TUNEL-positive
cells.
Northern blot analysis
The Trizole procedure (Life Technologies) was
employed for isolation of total RNA from cells. Electro-
phoresis in formaldehyde gels and Northern blot
analysis were performed as described.6 Quantification of
Northern hybridization signals was done with the
Cyclone Storage Phosphor System (Packard) and the
manufacturer’s software package.
Relative quantitative RT-PCR analysis
Total RNA from 293T cells was isolated using RNeasy
Mini Kit (Quagen). SuperScript One-step RT-PCR Kit
(Invitrogen) was employed for RT-PCR reactions. The
18 S rRNA Primers and Competimers (Ambion) were
used as for quantitative analysis of gene expression.
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Transient transfection and luciferase reporter assay
For transient transfection 293T or T-lymphoma Jurkat-
E6 cell lines were grown in six-well plates to 70–80%
confluence and co-transfected with the indicated
reporter constructs and the plasmids containing STRA13
(or its derivatives) and (or) STAT3a or b using Lipofecta-
mine2000 reagent (Stratagene). At 40 hours post-trans-
fection the recipient cells were divided, when needed,
into two equal volumes that were either left untreated
or treated for eight hours with 10 ng/ml of IL-6 (Calbio-
chem). After treatment luciferase activity was detected
by mixing 20 ml of the extract with 100 ml of luciferase
substrate (Promega) and measured in a MicroLumat
LB96P luminometer (EG&G Berthold). The luciferase
activity was normalized based on extract protein con-
centration. Fold induction was calculated by dividing
the treated samples by the non-treated control for each
reporter construct. Each experiment was repeated five
times, after that the mean and standard deviation were
calculated.
Co-immunoprecipitation and Western blot analysis
293T cells were transfected using Superfect (Quagen)
according to the manufacturer’s recommendations.
Forty eight hours after transfection the cells were lysed
in RIPA buffer (150 mM NaCl, 50 mM Hepes (pH 7.4),
10 mM NaF, 1 mM EDTA, 2 mM orthovanadate, 10%
(v/v) glycerol, 1% (v/v) Triton, 1% (w/v) deoxychelate,
0.5% (w/v) SDS, protease inhibitors), the lysates were
sheared by ultrasound and cleared by centrifugation at
13,000 rpm for 15 minutes at 4 8C. Cell lysates containing
equal amount of total protein were incubated for four
hours at 4 8C with 50 ml of 30% (w/v) protein G-Sepha-
rose beads (Stratagene) and anti-FLAG monoclonal anti-
body or control (IgG) antibodies. The beads were
washed extensively with lysis buffer and bound proteins
were fractionated on SDS/8–16% PAGE, transferred to
a nitrocellulose membrane, and incubated with the
anti-HA antibodies. Flag or HA-fused proteins were
visualized using the ECL kit (DURA, Pierce).
Yeast two-hybrid screen
The entire open reading frame of STRA13 (411
residues) was inserted into EcoRI-BamHI restriction
sites of the pAS2-1 expression vector (Clontech) that
was used as a bait. The two-hybrid screening was per-
formed as described.8
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